Page 820 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

798 PART IV Specific Malignancies in the Small Animal Patient

Comparative Aspects 12. Hargis AM, Ihrke PJ, Spangler QL, et al.: A retrospective clinico-
pathologic study of 212 dogs with cutaneous hemangiomas and
hemangiosarcomas, Vet Pathol 29:316–328, 1992.
Histiocytic neoplasia is extremely rare in people, and many pur-
VetBooks.ir ported cases were reclassified as lymphomas with the advent of 13. Nikula KJ, Benjamin SA, Angleton GM, et al.: Ultraviolet radia-
tion, solar dermatosis, and cutaneous neoplasia in Beagle dogs,
584
IHC and advanced molecular testing.
More recently, the dis-
Radiat Res 129:11–18, 1992.
ease has been better described and classified into HS, Langerhans 14. Szivek A, Burns RE, Gericota B, et al.: Clinical outcome in 94 cases
cell sarcoma, LCH, follicular dendritic cell sarcoma, interdigitat- of dermal haemangiosarcoma in dogs treated with surgical excision:
ing cell sarcoma, and indeterminate dendritic cell sarcoma. 585 HS 1993-2007, Vet Comp Oncol 10:65–73, 2012.
in humans presents in the LN in one-third of patients, in the skin 15. Ware WA, Hopper DL: Cardiac tumors in dogs: 1982-1995, J Vet
in one-third of patients, and in extranodal sites in the remain- Intern Med 13:95–103, 1999.
ing patients. The intestinal tract is the most common extranodal 16. Torres de la Riva G, Hart BL, Farver TB, et al.: Neutering dogs:
site and hepatosplenomegaly is common. Some patients may also effects on joint disorders and cancers in golden retrievers, PLOS
present with multiple anatomic sites of involvement and 70% of One 8:e55937, 2013.
patients present with advanced stage (III or IV) disease. 584 HS 17. Lamerato-Kozicki AR, Helm KM, Jubala CM, et al.: Canine
in humans is an aggressive neoplasm that is often refractory to hemangiosarcoma originates from hematopoietic precursors with
therapy and results in death in most patients. Similar to that in potential for endothelial differentiation, Exp Hematol 34:870–878,
2006.
dogs, hypoalbuminemia is associated with a poorer prognosis in 18. Fosmire SP, Dickerson EB, Scott AM, et al.: Canine malignant
people with histiocytic neoplasia. 585 Braf and MEK mutations hemangiosarcoma as a model of primitive angiogenic endothelium,
have been found in some cases of HS and other histiocytic neo- Lab Invest 84:562–572, 2004.
plasia types. 585,586 19. Gorden BH, Kim JH, Sarber AL, et al.: Identification of three
The results of a recent study using genome-wide array com- molecular and functional subtypes in canine hemangiosarcoma
parative genomic hybridization to evaluate copy number alterna- through gene expression profiling and progenitor cell characteriza-
tions suggest that canine HS may offer a valuable model for the tion, Am J Pathol 184:985–995, 2014.
human counterpart. 530 Extrapolation of data derived from canine 20. Tamburini BA, Phang TL, Fosmire SP, et al.: Gene expression pro-
histiocytic disorders to human histiocytic proliferation may help filing identifies inflammation and angiogenesis as distinguishing
features of canine hemangiosarcoma, BMC Canc 10:619, 2010.
further our understanding of the disease to promote the develop- 21. Thomas R, Borst L, Rotroff D, et al.: Genomic profiling reveals
ment of new and effective therapeutic modalities for both species. extensive heterogeneity in somatic DNA copy number aberrations
Because many of the recurrent genetic changes are evolutionarily of canine hemangiosarcoma, Chrom Res 22:305–319, 2014.
conserved with those reported in human histiocytic proliferations, 22. Naka N, Tomita Y, Nakanashi H, et al.: Mutations of p53 tumor-
this further points to a shared conserved pathogenesis. suppressor gene in angiosarcoma, Int J Cancer 71:952–955, 1997.
23. Arbiser JL, Moses MA, Fernandez CA, et al.: Oncogenic H-ras
References stimulates tumor angiogenesis by two distinct pathways, Proc Natl
Acad Sci USA 94:861–866, 1997.
24. Garcia JM, Gonzalez R, Silva JM, et al.: Mutational status of K-ras
1. Spangler WL, Culbertson MR: Prevalence, type, and importance and TP53 genes in primary sarcomas of the heart, Br J Cancer
of splenic diseases in dogs: 1,480 cases (1985-1989), J Am Vet Med 82:1183–1185, 2000.
Assoc 200:829–834, 1992. 25. Mayr B, Zwetkoff S, Schaffner G, et al.: Tumour suppressor gene
2. Prymak C, McKee LJ, Goldschmidt MH, et al.: Epidemiologic, p53 mutation in a case of haemangiosarcoma of a dog, Acta Vet
clinical, pathologic, and prognostic characteristics of splenic hem- Hung 50:157–160, 2002.
angiosarcoma and splenic hematoma in dogs: 217 cases (1985), 26. Yonemaru K, Sakai H, Murakami M, et al.: The significance of
J Am Vet Med Assoc 193:706–712, 1988. p53 and retinoblastoma pathways in canine hemangiosarcoma,
3. Brown NO, Patnaik AK, MacEwen EG: Canine hemangiosarcoma: J Vet Med Sci 69:271–278, 2007.
retrospective analysis of 104 cases, J Am Vet Med Assoc 186:56–58, 27. Dickerson EB, Thomas R, Fosmire P, et al.: Mutations of phospha-
1985. tase and tensin homolog deleted from chromosome 10 in canine
4. Clifford CA, de Lorimier LP: Hemangiosarcoma. In Ettinger SJ, hemangiosarcoma, Vet Pathol 42:618–632, 2005.
Feldman EC, Cote E, editors: Textbook of veterinary internal medi- 28. Murakami M, Sakai H, Kodama A, et al.: Expression of the anti-
cine, ed 8, St. Louis, 2017, Elsevier, pp 2093–2102. apoptotic factors Bcl-2 and survivin in canine vascular tumours,
5. Spangler WL, Kass PH: Pathologic factors affecting postsplenec- J Comp Pathol 139:1–7, 2008.
tomy survival in dogs, J Vet Intern Med 11:166–171, 1997. 29. Yonemaru K, Sakai H, Murakami M, et al.: Expression of vascu-
6. Schultheiss PC: A retrospective study of visceral and nonvisceral lar endothelial growth factor, basic fibroblast growth factor, and
hemangiosarcoma and hemangiomas in domestic animals, J Vet their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors, Vet
Diagn Invest 16:522–526, 2004. Pathol 43:971–980, 2006.
7. Yoon HY, Kang HM, Lee MY: Primary cranial mediastinal heman- 30. Dickerson EB, Marley K, Edris W, et al.: Imatinib and dasatinib
giosarcoma in a young dog, Ir Vet J 67(15), 2014. inhibit hemangiosarcoma and implicate PDGFR-β and Src in
8. KA Powers BE, Withrow SJ, et al.: Splenomegaly in dogs: predic- tumor growth, Transl Oncol 6:158–168, 2013.
tors of neoplasia and survival after splenectomy, J Vet Intern Med 31. Kodama A, Sakai H, Matsuura S, et al.: Establishment of canine
3:160–166, 1989. hemangiosarcoma xenograft models expressing endothelial growth
9. Tamburini BA, Trapp S, Phang TL, et al.: Gene expression profiles factors, their receptors, and angiogenesis-associated homeobox
of sporadic canine hemangiosarcoma are uniquely associated with genes, BMC Cancer 14:363, 2009.
breed, PLoS One 4:e5549, 2009. 32. Clifford CA, Hughes D, Beal MW, et al.: Plasma vascular endo-
10. Gamlem H, Nordstoga K, Arnesen K: Canine vascular neoplasia– thelial growth factor concentrations in healthy dogs and dogs with
a population-based clinicopathologic study of 439 tumours and hemangiosarcoma, J Vet Intern Med 15:131–135, 2001.
tumour-like lesions in 420 dogs, APMIS (Suppl)41–54, 2008. 33. Fukumoto S, Miyasho T, Hanazono K, et al.: Big endothelin-1 as
11. Johannes CM, Henry CJ, Turnquist SE, et al.: Hemangiosarcoma a tumour marker for canine hemangiosarcoma, Vet J 204:269–274,
in cats: 53 cases (1992-2002), J Am Vet Med Assoc 231:1851–1856, 2015.
2007.